Fresenius Medical Care

Humacyte Announces Presentation on Investigational Human Acellular VesselTM for Treatment of Vascular Trauma at the International Committee of Military Medicine World Congress

Retrieved on: 
Friday, September 9, 2022
Partnership, International Committee for the Nanking Safety Zone, COVID-19, Fresenius Medical Care, Technology, FACS, Allotransplantation, Program, World Congress, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Fast track (FDA), Amputation, Injury, Death, Accident, Tissue, Incidence, USAF, Infection, Food, ICMM, Physician, Forward-looking statement, SEC, HAV, EAP, GLOBE, Surgeon, Medicine, Patient, Intention, Moyamoya disease, Nasdaq, HUMA, FDA, Company, AV, Nursing, Vibration, Terminology, Gunshot, Annual report, Col, NATO, Disney International Programs, Dentistry, Pharmaceutical industry, Health, Defense

USAF MC), at the 44th International Committee of Military Medicine (ICMM) World Congress in Brussels, Belgium.

Key Points: 
  • USAF MC), at the 44th International Committee of Military Medicine (ICMM) World Congress in Brussels, Belgium.
  • Dr. Rasmussen added that vascular injury, whether in a military or civilian setting, is a leading cause of death and or amputation.
  • The incidence of vascular trauma in the modern combat setting has increased 5-fold over the past century.
  • Human Acellular Vessels (HAV) are investigational engineered off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction and replacement.

Fresenius Medical Care partners with National Kidney Foundation Malaysia in kidney health initiative

Retrieved on: 
Wednesday, September 7, 2022
General Health, Medical Devices, Other Health, Health, Medical Supplies, Partnership, NKF, Patient, Fresenius Medical Care, FMS, Kidney failure, Kidney, Program, Animation, Ageing, Health care, FME, Awareness, Chronic kidney disease, Critical care, Corporate social responsibility, CKD, Parent, Literacy, Character, National Kidney Foundation, Dialysis, Education, Organization, Multimedia, Hospital, Frankfurt Stock Exchange, New, U.S. Securities and Exchange Commission, School, App Store (iOS/iPadOS), Company, Internet, Memorandum of understanding, Boy, App store, Profile, CSR, Social media, Pharmaceutical industry, Toy, Health insurance, Asia-Pacific

Fresenius Medical Care, the worlds leading provider of products and services for individuals with renal diseases, today signed a memorandum of understanding (MoU) with the National Kidney Foundation (NKF) Malaysia, to work together in promoting kidney health and the prevention of chronic kidney disease amongst children and their families in Malaysia.

Key Points: 
  • Fresenius Medical Care, the worlds leading provider of products and services for individuals with renal diseases, today signed a memorandum of understanding (MoU) with the National Kidney Foundation (NKF) Malaysia, to work together in promoting kidney health and the prevention of chronic kidney disease amongst children and their families in Malaysia.
  • The organizations will leverage Fresenius Medical Cares international Corporate Social Responsibility (CSR) initiative, The Kidney Kid, to provide education and entertainment about kidney health to children and their carers.
  • View the full release here: https://www.businesswire.com/news/home/20220907005686/en/
    Fresenius Medical Care today signed a memorandum of understanding (MoU) with the National Kidney Foundation Malaysia, to work together in promoting kidney health and the prevention of chronic kidney disease amongst children and their families in Malaysia.
  • The Kidney Kid represents Fresenius Medical Cares commitment to building awareness of kidney health and assisting prevention of CKD in the diverse communities we serve.

Global Hemodialysis and Peritoneal Dialysis Market Analysis/Forecast 2022-2028: Market Strategies by Key Players & Shift in Preference of Patients for Home Care Dialysis - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 31, 2022
General Health, Health, Medical Supplies, Medical Devices, University, COVID-19, Emergency, Fresenius Medical Care, ESRD, Centers for Medicare & Medicaid Services, Disinfectant, Kidney, US FDA, Peritoneal dialysis, Patient, Chronic kidney disease, Solution, International Society, Artificiality, Baxter International, CMS, International Finance Corporation, International Society of Nephrology, Mayo Clinic, Health, Dialysis, Kidney disease, Prescription, HD, Hospital, Sodium bicarbonate, Gamma Zeta Alpha, Center, Nurses station, Medicare, Prevalence, CAGR, Adult, Diabetes, Growth, Adoption, Medical device

The presence of competitive market players introducing advanced products and services with innovative strategies acts as a future trend of the hemodialysis and peritoneal dialysis market.

Key Points: 
  • The presence of competitive market players introducing advanced products and services with innovative strategies acts as a future trend of the hemodialysis and peritoneal dialysis market.
  • The global hemodialysis and peritoneal dialysis market is segmented on the basis of type, product, and end user.
  • Additionally, the Regents of the University of California report states that various health centers offer quality hemodialysis and peritoneal dialysis services.
  • Such aforementioned factors would highly support the growth of the hemodialysis and peritoneal dialysis market during the forecast period.

CSL Vifor and Travere Therapeutics announce EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgA Nephropathy

Retrieved on: 
Monday, August 22, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, COVID-19, Jay Traver, Safety, Swelling, Heart Protection Study, Dialysis, CSL, U.S. Securities and Exchange Commission, Medicine, Company, ESKD, Risk, Patient, EMA, Fresenius Medical Care, Chronic kidney disease, Caregiver, Immunoglobulin A, Kidney, EGFR, Private Securities Litigation Reform Act, Proteinuria, Nephrology, Hematuria, Security (finance), NDA, Form 10-K, Therapy, NASDAQ, DUET, Irbesartan, Disease, Blood, Multimedia, Patent, ASX, Review, Marketing, ARB, File, Focal segmental glomerulosclerosis, CMA, Union, Edema, Urine, Life, Conditional, Pharmaceutical industry, EU, FSGS, IgA nephropathy

The EMA will review the application under the centralized marketing authorization procedure and a review decision on a potential approval is expected in the second half of 2023.

Key Points: 
  • The EMA will review the application under the centralized marketing authorization procedure and a review decision on a potential approval is expected in the second half of 2023.
  • We look forward to continuing to collaborate with our partners at CSL Vifor and with the EMA throughout the review process.
  • Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care).
  • There is no guarantee that the EMA will grant conditional marketing authorization of sparsentan for IgAN or that sparsentan will be approved at all.

Travere Therapeutics and CSL Vifor Announce EMA has Accepted for Review the Conditional Marketing Authorization Application for Sparsentan for the Treatment of IgA Nephropathy

Retrieved on: 
Monday, August 22, 2022
COVID-19, Jay Traver, Safety, Swelling, SAN, Heart Protection Study, Dialysis, CSL, U.S. Securities and Exchange Commission, GLOBE, Medicine, Company, ESKD, Risk, Patient, EMA, Fresenius Medical Care, Chronic kidney disease, Caregiver, Immunoglobulin A, Kidney, EGFR, Private Securities Litigation Reform Act, Proteinuria, Nephrology, Hematuria, Security (finance), NDA, Form 10-K, Therapy, NASDAQ, DUET, Irbesartan, Disease, Blood, Patent, ASX, Review, Marketing, ARB, File, Focal segmental glomerulosclerosis, CMA, Union, Edema, Urine, Life, Conditional, Pharmaceutical industry, EU, FSGS, IgA nephropathy

SAN DIEGO and ST. GALLEN, Switzerland, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) and CSL Vifor today announced that the EMA has accepted for review the Conditional Marketing Authorization (CMA) application for sparsentan for the treatment of IgAN, a rare kidney disorder and leading cause of end-stage kidney disease (ESKD). The EMA will review the application under the centralized marketing authorization procedure and a review decision on a potential approval is expected in the second half of 2023.

Key Points: 
  • The EMA will review the application under the centralized marketing authorization procedure and a review decision on a potential approval is expected in the second half of 2023.
  • We look forward to continuing to collaborate with our partners at CSL Vifor and with the EMA throughout the review process.
  • If approved, sparsentan would receive CMA in all member states of the European Union, as well as in Iceland, Liechtenstein and Norway.
  • There is no guarantee that the EMA will grant conditional marketing authorization of sparsentan for IgAN or that sparsentan will be approved at all.

VFMCRP announces U.S. Court upholds validity of Velphoro® patent

Retrieved on: 
Monday, August 22, 2022
Medical Supplies, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Orange Book, Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., Fresenius Medical Care, District court, Sucroferric oxyhydroxide, Chronic kidney disease, Teva, Vifor Pharma, Judgement, Blood, Dialysis, CSL, Patent, Multimedia, Nephrology, ANDA, District, Douglas v. U.S. District Court ex rel Talk America, Abbreviated New Drug Application, ASX, Intellectual property, Anders (singer), Marketing, Patient, Generic drug

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the U.S. District Court for the District of Delaware issued a judgment in VFMCRPs favor regarding U.S. patent no.

Key Points: 
  • Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the U.S. District Court for the District of Delaware issued a judgment in VFMCRPs favor regarding U.S. patent no.
  • Currently, Velphoro is protected by multiple Orange Book listed patents which expire between May 2029 and May 2035.
  • View the full release here: https://www.businesswire.com/news/home/20220821005007/en/
    A further ANDA patent infringement lawsuit against Teva based on patents no.
  • CSL Vifor welcomes the decision by the U.S. District Court to uphold the patent validity of Velphoro which highlights the innovation and strength of our intellectual property, said Florian Jehle, Chief Executive Officer of VFMCRP.

Tavneos® (avacopan) recommended by England’s NICE for the treatment of AAV (GPA/MPA)

Retrieved on: 
Thursday, August 18, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Vasculitis, Receptor (biochemistry), Multimedia, Dialysis, Risk, NICE, Inflammation, C5a, National Health Service, Population, Neutrophil, Failure, University of Cambridge, ANCA, Atypical hemolytic uremic syndrome, ASX, Rituximab, European Commission, Steroid, CSL, Patient, Quality of life, Marketing, Cell, Hidradenitis suppurativa, Granulomatosis with polyangiitis, Anti-neutrophil cytoplasmic antibody, HS, Nephrology, MHRA, Prednisolone, Kidney, MPA, Fresenius Medical Care, GPA, Glucocorticoid, Lung, Microscopic polyangiitis, University, Cyclophosphamide, Time, Regulation of tobacco by the U.S. Food and Drug Administration, Medicine, Food, Adult, AAV, Disease, Health care, Pharmaceutical industry

We very much welcome NICEs decision, which means that eligible patients and clinicians have another choice of treatment for this debilitating condition.

Key Points: 
  • We very much welcome NICEs decision, which means that eligible patients and clinicians have another choice of treatment for this debilitating condition.
  • NICEs decision represents a major advancement for the treatment of GPA/MPA in the UK, said Prof. David Jayne, Professor of Clinical Autoimmunity, University of Cambridge.
  • Patients will now have access to a new therapy option that could help them optimize their treatment outcomes.
  • Tavneos was developed by ChemoCentryx, Inc., who is also developing Tavneos for the treatment of patients with C3 Glomerulopathy (C3G) and hidradenitis suppurativa (HS).

Row Associates Presents Healthcare rpm 2022

Retrieved on: 
Wednesday, August 10, 2022
Virginia Scholastic Rowing Association, Securities & Exchange Commission of Pakistan, Partner (business rank), Nashville Songwriters Hall of Fame, FINRA, River, Music, Industry, Science, McKesson Corporation, Leadership, Semantic Web, LLC, Songwriter, Medidata Solutions, Rivers Rutherford, General Atlantic, Doctor of Philosophy, Country Music Hall of Fame and Museum, U.S. Securities and Exchange Commission, Daniel T. McCarty, Fresenius Medical Care, General Electric, Country song, MD, Infusion, Entrepreneurship, Former, ASCAP, FACP, Management, Hospital, Health care

NASHVILLE, Tenn., Aug. 10, 2022 /PRNewswire/ --Row Associates, a healthcare-focused strategic advisory firm, is pleased to present and host Healthcare rpm 2022 at the renowned Country Music Hall of Fame and Museum in downtown Nashville, Tennessee.

Key Points: 
  • NASHVILLE, Tenn., Aug. 10, 2022 /PRNewswire/ --Row Associates, a healthcare-focused strategic advisory firm, is pleased to present and host Healthcare rpm 2022 at the renowned Country Music Hall of Fame and Museum in downtown Nashville, Tennessee.
  • Healthcare rpm is anchored in important conversations, moderated by key industry figures, with C-suite leadership from vibrant segments of the healthcare landscape where significant change is actively taking shape.
  • In connection with Healthcare rpm 2022, Row Associates is pleased to announce the following areas of discussion and thought leadership for this year's event:
    Frank Maddux, MD, FACP Global Chief Medical Officer, Fresenius Medical Care
    Michael Uchrin Co-Founder and Chief Executive Officer, Monogram Health
    Doug Ghertner Chief Executive Officer, IVX Health
    Chuck Jett Chief Executive Officer, Infusion Associates
    Dan McCarty Chief Executive Officer, Infusion for Health
    Catherine Swick Vice President / General Manager, Intrafusion by McKesson
    An interactive presentation regarding applications for Web 3.0 across the areas of discussion at Healthcare rpm with John Bass, Chief Executive Officer, Hashed Health and Former Chief Executive Officer, InVivoLink.
  • Row Associates LLC is registered as a Capital Acquisition Broker with the U.S. Securities and Exchange Commission and is a member of FINRA andSIPC.

CytoSorbents Reports Second Quarter 2022 Financial and Operational Results

Retrieved on: 
Tuesday, August 2, 2022
Bridge bank, Sale, Cytosorbents Corporation, Cytokine, Treatment, ATM, DSMB, Physician, Myoglobin, Professional corporation, Parity, Anomaly, Research, Perfusion, SG, Hospital, Bilirubin, Social media, Critical care, DCD, Partnership, Advertising, Travel, Fresenius, Marketing, Fresenius Medical Care, COVID-19, NASDAQ, Certification, Currency, Lung transplantation, Liver, FDA, Company, Patient, COVID, Acceleration, Secretary of State of New Jersey, Comparison, Data monitoring committee, Kidney, Growth, Population, Form, Pharmaceutical industry, Bank, Health insurance, Online gambling, Medical device, Financial services, Animal, Security (finance), Non-contact normothermic wound therapy, Princeton University, Cytokine adsorbing column, Euro

Comparison for the three months ended June 30, 2022 and 2021:

Key Points: 
  • Comparison for the three months ended June 30, 2022 and 2021:
    Total revenue, including product revenue and grant income, for the second quarter of 2022 was $8.5 million, down 39% from $12.0 million in the second quarter of 2021.
  • We estimate that demand for CytoSorb to treat COVID-19 patients was de minimis in the second quarter of 2022 as compared to approximately $1.7 million in the second quarter of 2021.
  • For additional information, please see the Company's Form 10-Q for the period ended June 30, 2022 filed on August 2, 2022 on http://www.sec.gov .
  • The Company will conduct its second quarter 2022 results call today at 4:30 p.m. Eastern time.

Aesthetics Biomedical® Hires Two New Executives to Join the Company's Leadership Team to Fuel Growth Trajectory

Retrieved on: 
Wednesday, July 27, 2022
Allergan, Clinical, Physician, Administration, NMD, Industry, Telehealth, Research, Compliance, Marketing, Board, IG, Merck, COVID-19, ABM, Beauty, Leadership, Quality assurance, Some, Business development, RealSelf, Patient, Microneedle, Regulation, Fresenius Medical Care, Health, Growth, Regulatory affairs, Founder, Dermatology, Medical device, Pharmaceutical industry, Cynosure

PHOENIX, July 27, 2022 /PRNewswire-PRWeb/ -- Aesthetics Biomedical® Inc. (ABM), in its ongoing efforts to meet the increasing demand for its revolutionary aesthetic products and distribution growth, is continuing to build its executive team recruiting top industry experts Derek Harmon as Vice President of U.S. Sales and Don Selvey, NMD, MS as Vice President of Regulatory respectively. Mr. Harmon and Dr. Selvey will play pivotal roles in the company's expansion and national distribution of current products including the legacy Vivace® Microneedle RF treatment and device, SoME® PRP Skincare and focus on the new era of energy-based technology with Vivace Ultra™, with expected FDA Clearance, is expected to roll-out via limited commercial release in the fall to top tier plastic surgeons, dermatologists, and medical aesthetic practitioners across the country.

Key Points: 
  • "I'm honored to be joining an organization about to reignite aesthetics with Vivace Ultra and SoME PRP Skincare," says Derek Harmon.
  • "I'm impressed with what the team has created that uniquely positions ABM as a leader in this industry", he continued.
  • Mr. Harmon brings an award-winning, 20+ year career of industry expertise, results, and leadership to the ABM Executive Team.
  • ABOUT AESTHETICS BIOMEDICAL: Aesthetics Biomedical Inc., headquartered in Phoenix, Ariz., is committed to the development and distribution of novel aesthetic devices, products, and services in the global market.